IP Library Granted Patent US 8,029,755
Granted Patent B2
US 8,029,755 · App. 10/635,402 · Granted Oct 4, 2011

Tricalcium phosphates, their composites, implants incorporating them, and method for their production

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,029,755
App. No.
10/635,402
Granted
Oct 4, 2011
Kind
B2
Abstract

Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.

Claims (27)

1. A composition comprising particulate tricalcium phosphate (TCP) having an average particle size of about 5 μm or less, an average crystal size of about 250 nm or less and a surface area of about 20 m 2 /g or greater, wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article transmits about 50% or more light having a wavelength in the range of about 150 nm to about 1,000 nm.

2. The composition of claim 1 , wherein the particulate TCP has an average particle size of about 1 μm or less.

3. The composition of claim 1 , wherein the particulate TCP has an average crystal size of about 200 nm or less.

4. The composition of claim 1 , wherein the particulate TCP comprises α-TCP.

5. The composition of claim 1 , wherein the particulate tricalcium phosphate is densified.

6. The composition of claim 1 , further comprising a secondary additive.

7. The composition of claim 6 , wherein the secondary additive is present in an amount of between about 1% and about 50% by volume.

8. The composition of claim 6 , wherein the secondary additive comprises a structural additive.

9. The composition of claim 8 , wherein the structural additive comprises a metal oxide.

10. The composition of claim 9 , wherein the metal oxide comprises zirconia.

11. The composition of claim 8 , wherein the structural additive has an aspect ratio of about 2 or greater.

12. The composition of claim 6 , wherein the secondary additive is an organic species.

13. The composition of claim 6 , wherein the secondary additive is a polymeric additive.

14. The composition of claim 13 , wherein the polymeric additive is selected from the group consisting of polylactic acid, polyglycolic acid, polylactic/polyglycolic acid copolymers, polypropylenefumarate, polyhydroxybutyric acid, polyhydroxyvaleric acid, polycaprolactone, polyhydroxycarboxylic acids, polybutyrene succinate, polybutylene adipate, collagen, chitosan, alginate, celluloses, starches, sugars, polypeptides, polyethylene glycols, vinyl pyrrolidones, acrylamides, methacrylates, copolymer micelles, and combinations thereof.

15. The composition of claim 6 , wherein the secondary additive is a biological additive.

16. The composition of claim 15 , wherein the biological additive is selected from the group consisting of plasmid DNA, RNA, proteins, bone morphogenetic proteins, and combinations thereof.

17. The composition of claim 6 , wherein the secondary additive is a pharmaceutical additive.

18. The composition of claim 1 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article has a compressive strength of 150 MPa or greater.

19. The composition of claim 1 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article transmits about 70% or more light having a wavelength in the range of about 150 nm to about 1,000 nm.

20. The composition of claim 1 , wherein the particulate TCP comprises β-TCP.

21. The composition of claim 1 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article has a density that is 90% of the theoretical density or greater.

22. The composition of claim 1 , wherein the particulate TCP is produced using a wet chemical approach.

23. The composition of claim 22 , wherein the wet chemical approach comprises (i) precipitating a TCP precursor material from a solution containing a calcium salt and a phosphate source, (ii) recovering the TCP precursor material, (iii) milling the TCP precursor material to form a powder, and (iv) transforming the TCP precursor powder to form particulate TCP.

24. The composition of claim 23 , wherein the TCP precursor powder is transformed to particulate TCP by calcination.

25. A composition comprising particulate tricalcium phosphate (TCP) having an average particle size of about 5 μm or less, an average crystal size of about 250 nm or less and a surface area of about 20 m 2 /g or greater, wherein the particulate TCP is produced using a wet chemical approach, and wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article has a density that is 90% of the theoretical density or greater.

26. The composition of claim 24 , wherein the wet chemical approach comprises (i) precipitating a TCP precursor material from a solution containing a calcium salt and a phosphate source, (ii) recovering the TCP precursor material, (iii) milling the TCP precursor material to form a powder, and (iv) transforming the TCP precursor powder to form particulate TCP.

27. The composition of claim 25 , wherein the TCP precursor powder is transformed to particulate TCP by calcination.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Jul 21, 2020
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.
Reel/Frame 053260/0398 →
RELEASE OF SECURITY INTEREST Recorded Jul 20, 2020
From: ARES CAPITAL CORPORATION, AS AGENT
To: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.; PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
Reel/Frame 053257/0652 →
SECURITY INTEREST Recorded Mar 8, 2019
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.; PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 048543/0505 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2018
From: TD BANK, N.A., AS ADMINISTRATIVE AGENT
To: PIONEER SURGICAL TECHNOLOGY, INC., SUCCESSOR IN INTEREST TO ANGSTROM ACQUISITION CORP. II
Reel/Frame 046016/0524 →
SECURITY INTEREST Recorded Jun 6, 2018
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A., AS THE ADMINISTRATIVE AGENT
Reel/Frame 046303/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2013
From: ANGSTROM MEDICA, INC.
To: ANGSTROM ACQUISITION CORP. II
Reel/Frame 031657/0065 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2013
From: ANGSTROM ACQUISITION CORP. II
To: PIONEER SURGICAL TECHNOLOGY, INC.
Reel/Frame 031133/0219 →
SECURITY AGREEMENT Recorded Jul 29, 2013
From: ANGSTROM ACQUISITION CORP. II
To: TD BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 030910/0675 →